Last reviewed · How we verify
L-Citrulline (Citrulline)
At a glance
| Generic name | Citrulline |
|---|---|
| Sponsor | Nantes University Hospital |
| Drug class | Standardized Chemical Allergen [EPC] |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Circulation support
- Fatigue relief
Common side effects
Key clinical trials
- Effect of a Daily Supplement on Plasma PAI-1 Levels (PHASE1,PHASE2)
- L-Citrulline and Endothelial Function (PHASE1)
- COMP-4 Supplementation and Brachial Artery FMD (PHASE1,PHASE2)
- L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients) (NA)
- Effect of NO Precursors on Physiological Responses to Exercise (NA)
- Effect of Watermelon on Gut and Cardiometabolic Health (NA)
- Effect of Citrulline Malate Supplementation on Physical Function and Biochemical Parameters in Physically Active Older Women (NA)
- CHF COPD Sip Feed Anabolic Response (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Citrulline CI brief — competitive landscape report
- L-Citrulline updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI